NCT01438853 - Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

July 31, 2006

Study Completion Date

February 29, 2008

Conditions

SepsisAcute Lung InjuryAcute Respiratory Distress Syndrome

Interventions

BIOLOGICAL

TNX-832

Single intravenous dose of TNX-832 at 0.06, 0.08 or 0.10 mg/kg

DRUG

Placebo

Single intravenous dose of saline control

Trial Locations (7)

Wake Forest University, Winston-Salem

University of Miami, Miami

Akron General Medical Center, Akron

Washington University, St Louis

Baylor School of Medicine, Houston

Beth Israel Deconess Medical Center, Boston

Capital Health, Halifax